Archives
-
Thiazovivin (A5506): ROCK Inhibitor Workflow Guide
2026-09-15
Thiazovivin (A5506) is a ROCK inhibitor used to address poor cell recovery after dissociation and to support fibroblast reprogramming for induced pluripotent stem cell generation. This dossier-based guide covers preparation, controls, and troubleshooting for stem cell research; it is not a clinical, diagnostic, or universal dosing protocol.
-
Estradiol, ER Signaling, and CD4+ T-Cell Recovery
2026-09-15
This study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Its receptor-selective experiments indicate that estradiol restores immune-cell proliferation and cytokine production primarily through ERα and GPR30-associated signaling, rather than ERβ, providing a useful framework for studying post-traumatic immune dysfunction.
-
Cell Lysis Buffer for WB and IP in CAF Studies
2026-09-14
Discover how Cell lysis buffer for WB and IP supports native protein extraction, phosphoprotein preservation, and co-IP analysis in cancer-associated fibroblast research. This assay-focused guide translates the CAF–ANGPTL4–IQGAP1 findings into practical decisions for Western blot and immunoprecipitation workflows.
-
Chenodeoxycholic Acid: FXR Workflow & Uses
2026-09-14
Chenodeoxycholic Acid offers a practical way to connect FXR activation with transcriptional, inflammatory, and renal injury readouts. This guide translates recent CDCA–FXR–KLF11 findings into executable cell-based workflows, assay controls, and troubleshooting strategies for metabolic and kidney research.
-
Imatinib hydrochloride: Applied Kinase Research Workflows
2026-09-13
Build reproducible kinase-inhibition assays around Imatinib hydrochloride, from DMSO stock preparation to phospho-signaling and viability readouts. The workflow also translates a recent conformational-kinase study into practical controls without overstating what is established for imatinib.
-
AZD3463: ALK/IGF1R Inhibitor Workflow
2026-09-12
AZD3463 combines ALK and IGF1R pathway targeting with a practical workflow for mutation-aware neuroblastoma studies, pathway pharmacodynamics, and chemotherapy combinations. This guide translates the compound’s reported activity into reproducible setup, dosing, assay, and troubleshooting decisions while keeping evidence-backed findings separate from proposed optimization steps.
-
GDC-0994: ERK1/2 Inhibition Workflows
2026-09-11
GDC-0994 is a potent, selective ERK1/2 inhibitor for connecting pathway engagement with measurable changes in cancer-cell behavior and cholestatic liver injury. This workflow-focused guide covers formulation, phospho-ERK and phospho-p90RSK assays, zebrafish rescue experiments, comparative model selection, and practical troubleshooting.
-
Deferoxamine Mesylate for Iron-Stress Assays
2026-09-11
Deferoxamine mesylate gives researchers a practical way to separate iron-dependent oxidative injury from hypoxia signaling, ferroptosis, and repair phenotypes. This guide translates its solubility, chelation activity, and HIF-1α effects into reproducible cell, tumor, wound-healing, and radiation-response workflows.
-
V5 Epitope Tag Peptide: Kinetics to Assay Design
2026-09-10
The V5 Epitope Tag Peptide is more than a recognition sequence: it is a practical control for separating antibody specificity, binding kinetics, and assay performance. This guide connects the GKPIPNPLLGLDST peptide with evidence from single-molecule antibody screening and rigorous workflow design.
-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Assays
2026-09-10
PP 3 provides a practical negative-control arm for experiments testing whether PP 2 effects truly depend on Src kinase activity. Its value is greatest in matched biochemical, cellular, and vascular workflows where DMSO exposure, concentration, timing, and orthogonal readouts are controlled rigorously.
-
SCH772984 HCl: Practical ERK1/2 Inhibition Workflows
2026-09-09
SCH772984 HCl is a nanomolar ERK1/2 inhibitor for dissecting MAPK-driven proliferation, resistance, and spatial translation. This guide connects cancer-focused workflows with cardiomyocyte assays inspired by recent findings on nuclear ERK and 4EBP1 phosphorylation, while emphasizing controls, timing, and troubleshooting.
-
2,2,2-Trichloroethanol: Reliable Protein Analysis
2026-09-09
Learn how 2,2,2-Trichloroethanol, SKU C6823, can support standardized protein electrophoresis and molecular biology workflows without being misrepresented as a direct cell-viability reagent. This scenario-based guide covers compatibility, handling, vendor selection, data interpretation, and limitations using product documentation and relevant translational research.
-
ICAA Targets RIP3 in Cardiac Hypertrophy
2026-09-09
A 2026 Cellular Signalling study identifies receptor-interacting protein 3 (RIP3) as a previously underappreciated regulator of angiotensin II- and pressure overload-induced cardiac hypertrophy. Its data position the RIP3/CaMKII axis, rather than the canonical RIP3/MLKL necroptosis pathway alone, as a mechanistic target of isochlorogenic acid A (ICAA).
-
Trametinib and Tumor Evolution in CRC Models
2026-09-08
Trametinib (GSK1120212) is more than a potent MEK1/2 inhibitor: it can serve as an evolution-aware oncology research tool for connecting ERK suppression with heterogeneous colorectal cancer responses. This article integrates its mechanism with patient-derived xenograft and multi-omics insights from metastatic CRC research.
-
AG-126 (Tyrphostin AG-126): ERK Pathway Guide
2026-09-07
AG-126, also called Tyrphostin AG-126, is a research inhibitor of ERK1 and ERK2 phosphorylation with reported in vitro activity at 25–50 μM. Product evidence also describes cytokine release inhibition and activity in a rat pneumococcal cell wall inflammation model, but it does not establish clinical efficacy or a role in autism-related repetitive behavior.